Therapeutic antibodies for human diseases at the dawn of the twenty-first century (Q34168125)

31 July 2017

1 reference

title

Therapeutic antibodies for human diseases at the dawn of the twenty-first century (English)

1 reference

31 July 2017

1 reference

2

Inger Sandlie

1 reference

31 July 2017

Ole Henrik Brekke

1

1 reference

31 July 2017

1 January 2003

1 reference

Nature Reviews Drug Discovery

31 July 2017

1 reference

31 July 2017

2

1 reference

31 July 2017

1

1 reference

31 July 2017

52-62

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd984

31 July 2017

0 references

cites work

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

31 March 2020

1 reference

Production of functional chimaeric mouse/human antibody

31 March 2020

1 reference

Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease

31 March 2020

1 reference

Replacing the complementarity-determining regions in a human antibody with those from a mouse

31 March 2020

1 reference

Assembly of a functional immunoglobulin Fv fragment in Escherichia coli

31 March 2020

1 reference

Escherichia coli secretion of an active chimeric antibody fragment.

31 March 2020

1 reference

Phage antibodies: filamentous phage displaying antibody variable domains

31 March 2020

1 reference

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

31 March 2020

1 reference

Signaling antibodies in cancer therapy

31 March 2020

1 reference

A review of interleukin-2 receptor antagonists in solid organ transplantation

31 March 2020

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

31 March 2020

1 reference

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

31 March 2020

1 reference

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

31 March 2020

1 reference

A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments

31 March 2020

1 reference

Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells

31 March 2020

1 reference

Production and characterization of protective human antibodies against Shiga toxin 1

31 March 2020

1 reference

Preventing infectious disease with passive immunization

31 March 2020

1 reference

Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

31 March 2020

1 reference

Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).

31 March 2020

1 reference

The antiviral activity of antibodies in vitro and in vivo.

31 March 2020

1 reference

Antibodies, viruses and vaccines

31 March 2020

1 reference

Treating human autoimmune disease by depleting B cells

31 March 2020

1 reference

Identification of colon tumour-associated antigens by phage antibody selections on primary colorectal carcinoma

31 March 2020

1 reference

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

31 March 2020

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

31 March 2020

1 reference

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

31 March 2020

1 reference

Bispecific human IgG by design

31 March 2020

1 reference

IgA antibodies for cancer therapy

31 March 2020

1 reference

Bispecific antibodies targeting cancer cells

31 March 2020

1 reference

Engineering antibodies for therapy

31 March 2020

1 reference

Formatting antibody fragments to mediate specific therapeutic functions

31 March 2020

1 reference

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

31 March 2020

1 reference

Triabodies: single chain Fv fragments without a linker form trivalent trimers

31 March 2020

1 reference

Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting.

31 March 2020

1 reference

"Diabodies": small bivalent and bispecific antibody fragments

31 March 2020

1 reference

Complement recruitment using bispecific diabodies.

31 March 2020

1 reference

Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma

31 March 2020

1 reference

Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody

31 March 2020

1 reference

Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells

31 March 2020

1 reference

Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics

31 March 2020

1 reference

31 March 2020

Troybodies and pepbodies

1 reference

Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection

31 March 2020

1 reference

Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display

31 March 2020

1 reference

Stability engineering of antibody single-chain Fv fragments

31 March 2020

1 reference

A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties

31 March 2020

1 reference

Multiple roles for the major histocompatibility complex class I- related receptor FcRn

31 March 2020

1 reference

PEGylated antibodies and antibody fragments for improved therapy: a review

31 March 2020

1 reference

Polymer modification of antibody to eliminate immune complex and Fc binding

31 March 2020

1 reference

Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobulin G

31 March 2020

1 reference

"Troy-bodies": recombinant antibodies that target T cell epitopes to antigen presenting cells

31 March 2020

1 reference

Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells.

31 March 2020

1 reference

The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination

31 March 2020

1 reference

Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells

31 March 2020

1 reference

Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics

31 March 2020

1 reference

Directed evolution of high-affinity antibody mimics using mRNA display

31 March 2020

1 reference

In vitro display technologies - new tools for drug discovery

31 March 2020

1 reference

Hybrid hybridomas and their use in immunohistochemistry

31 March 2020

1 reference

Humanization of a mouse monoclonal antibody by CDR–grafting: the importance of framework residues on loop conformation

31 March 2020

1 reference

A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells.

31 March 2020

1 reference

Antibody arrays for high-throughput screening of antibody-antigen interactions

31 March 2020

1 reference

The development of monoclonal antibodies for the therapy of cancer.

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD984

1 reference

release_lvumntx6bjbenjbu3e5bikwwsm

31 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lvumntx6bjbenjbu3e5bikwwsm

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

12509759

1 reference

PubMed ID

12509759